Spectral Medical Provides June Tigris Trial Update

116 patients enrolled June represents a new record breaking month for patient enrollment TORONTO, Canada – July 2, 2024 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis...
Read More

Spectral Medical Provides April Tigris Trial Update

105 patients enrolled April represents a record breaking month for patient enrollment  TORONTO, Canada – May 6, 2024 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and...
Read More

Spectral Medical Provides Tigris Trial Update

TORONTO, Canada – April 10, 2024 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3...
Read More
Click to Hide Advanced Floating Content
EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.